Hopkins Peter Mark Anthony
Queensland Heart-Lung Transplant Unit, The Prince Charles Hospital, Chermside, Brisbane, Queensland, Australia.
Methods Mol Biol. 2006;333:375-400. doi: 10.1385/1-59745-049-9:375.
Immunosuppressive strategies continue to evolve, with a number of new formulations having been developed in recent years. Although acute rejection rates may have diminished, current protocols of immunosuppression for chronic organ rejection are clearly inadequate. This complication remains the primary cause of graft loss months to years after solid organ transplant. In summary, the overall goal of achieving immune tolerance remains elusive. This chapter will focus on the pharmacological manipulation of the rejection response, reviewing historical and current recommended protocols. A brief outline of potential future pathways of targeted immunosuppression is described.
免疫抑制策略不断发展,近年来已开发出多种新的制剂。尽管急性排斥反应率可能有所下降,但目前针对慢性器官排斥反应的免疫抑制方案显然并不充分。这种并发症仍然是实体器官移植数月至数年后移植物丢失的主要原因。总之,实现免疫耐受的总体目标仍然难以实现。本章将重点讨论对排斥反应的药物控制,回顾历史和当前推荐的方案。还将概述靶向免疫抑制未来可能的途径。